KAMPALA: Cipla Quality Chemicals Limited (CiplaQCIL) joined other stakeholders in drug manufacturing, storage, regulation, and sales to participate in the East Africa Pharmatech Pharmaceutical and Healthcare Exhibition at UMA Show Grounds Lugogo, Kampala. The East Africa Pharmatech Exhibition which started on Tuesday will run till Thursday, March 24, 2022.
Speaking on the sidelines of the launch of Uganda’s Premier International Exhibition, which focuses on pharmaceuticals, medical and healthcare technology, Ajay Pal, the CiplaQCIL Chief Executive Officer, said the company has over the years been driven by the need to create solutions that help to solve some of Africa’s biggest problems and help to save lives.
“We want people to know that we are focused on creating solutions. In line with our ethos of “Caring for Life”, we want to create an environment where Africans, and Ugandans in particular, have equitable access to life-saving medication. We’re focused on Africa for Africa,” he said.
CiplaQCIL has been a forerunner in terms of creative problem solving over the years. At the height of the HIV pandemic in Africa, the company manufactured antiretroviral at a fraction of the cost, thereby saving millions of lives.
Recently, it ensured equitable access to health-related information through a unique, educational HIV/AIDS game. And during the COVID-19 pandemic, it focused on medicines such as Cipladon, which helps to relieve some of the symptoms of COVID-19 such as body aches and pains, and also found novel ways to transport medicine to places in need.
CiplaQCIL is Uganda’s largest medicine manufacturer, specialising in World Health Organization (WHO) pre-qualified medicines for HIV, tuberculosis, and antimalarial drugs.
About Cipla QCIL:
Cipla Quality Chemical Industries Limited (CiplaQCIL) is East Africa’s largest pharmaceutical manufacturer and one of the largest in Sub-Saharan Africa (SSA). It is one of the few pharmaceutical manufacturers in SSA to operate a World Health Organization (WHO) certified GMP compliant facility that manufactures a range of WHO prequalified medicines, in CiplaQCIL’s case ARV’s for the treatment of HIV/AIDS and ACTs for the treatment of malaria.